Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Nov 12, 2020- IDE397, a potential best-in-class MAT2A inhibitor for patients with solid tumors having MTAP deletion, targeting an IND-filing in December 2020
-
Oct 22, 2020- The partnership with the Sellers Laboratory at the Broad Institute of MIT and Harvard will utilize the Broad CRISPR paralog screening platform for Synthetic Lethality target and biomarker discovery, including for IDEAYA's PARG program
-
Aug 12, 2020- Established strategic partnership with GlaxoSmithKline on Synthetic Lethality programs MAT2A, Pol Theta and Werner Helicase
-
Aug 4, 2020- Closing of Glaxo Group Equity Investment of $20 Million in IDEAYA at $15.00 per share
-
Jul 16, 2020- 4 evaluable GNAQ/11 mutation skin melanoma patients enrolled in Stage 1 cohort with a 100% Disease Control Rate (excluding 1 non-evaluable) and 1 confirmed partial response by RECIST 1.1 guidelines
